Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2804_Библиотеки_им_академика_М_И_Перельмана
.pdf
expiratorywheezes.
A thorough examination should always be performed, observing any manifestations suggesting
underlyingcardiopulmonary,infectious,immunologic,ormalignantdisease.
DifferentialDiagnosis
Onemustdistinguishbetweentruehemoptysisandpseudohemoptysis,whichcomesfromtheupper
airway(abovetheglottis),oraspiratedGItractbleedingthatislaterexpectorated.
DiagnosticTesting
Athoroughhistoryandphysicalexaminationisimportanttoprovidecluesandguidanceinadditional
testing.
Additional testing is aimed at determining and localizing the bleeding source and identifying the
underlyingetiology.
LABORATORIESANDELECTROCARDIOGRAPHY
BasiclabworkincludingCBC,comprehensivemetabolicpanel,andcoagulationstudiesareindicated.
Typeandcross-matchingofbloodareindicated,especiallyincasesofmassivehemoptysis.
AnABGanalysismaybeindicatedincasesofshortnessofbreathorrespiratorycompromise.
Sputumstudiesmaybehelpfulincases ofinfectionandcanbeanalyzedwithroutineGram stainand
culture,fungalculture,andacid-fastbacillismear/cultureasindicated.
Serologicstudies andurinalysiswithmicroscopymaybeclinicallyindicatedbased onthesuspicion
for rheumatologic disease or vasculitis. These mayinclude ANA screen, antineutrophil cytoplasmic
antibody(ANCA)screen,includingreflextestingtomyeloperoxidaseandproteinase3,antiglomerular
basement membraneantibodies, complementlevels, cryoglobulins, double-strandedDNAantibodies,
andothers.
Brain natriuretic peptide or N-terminal pro b-type natriuretic peptide levels may be helpful when
cardiacfailureissuspected.
ECGcanhelpassessforunderlyingcardiacdisease.
IMAGING
PosteroanteriorandlateralCXRareperformedinallcasesofhemoptysis.
Unfortunately,thesemaybenormalornonlocalizinginupto50%ofallcases.
123,124
Furthermore, CXR may be normal in up to 10% of hemoptysis cases caused by bronchogenic
carcinoma.
123
ChestCT:CTshouldbeperformed ifthe diagnosisremainsindoubtafterinitialclinical andCXR
evaluation (see Figure 10-5). CT chest can be performed with or without contrast; however, CT
angiographyisincreasinglyusefulinlocalizingthesourceofhemoptysis.
Advantages:
Canvisualizeparenchyma,vasculature,andairwaystovaryingextent.
Especially useful for hemoptysis resulting from bronchiectasis, cavitary lung disease,
masses,andvascularmalformations.
125
Candetectupto96%ofCXR-occultmalignancies.
126
CTvisualizestumorswithefficacycomparablewithbronchoscopy.
127
CT angiography may be better than bronchoscopy in determining the etiology and source of
hemoptysis.
128
https://t.me/med1917

CTangiographyisusefulforplanningembolizationprocedures.
129
Disadvantages:
CTislessefficaciousthanbronchoscopyinrecognizingsubtlebronchialandmucosallesions.
125
Itisnonspecificincasesofparenchymal/alveolarhemorrhage.
Delayintreatmentplacesunstablepatientsathighrisk.
Echocardiographymaybeperformedifstructuralorvalvularcardiacdiseaseissuspected.
DIAGNOSTICPROCEDURES
Fiber-optic(flexible) bronchoscopy:Generallylocalizes/lateralizes bleedingsource inover two-
thirdsofcases,dependingonthesetting.
130
Indications:
Ifthesourceisunclearafterinitialevaluationandimaging
Persistentorrecurrenthemoptysis
Toruleoutinfection
Iftheclinicalpresentationsuggestsanairwayabnormality
Toobtainbiopsyspecimens,ifimagingsuggestsmalignancyorisnonlocalizinginthepresenceof
atleasttworiskfactorsforbronchogeniccarcinoma:
□ Malesex
□ Age>40years
□ >40pack-yearsmoking
□ Durationofhemoptysis>1week
□ Volumeexpectorated>30mL6,
131,132
Toidentifypotentialanatomicareaforarterialembolization
Toprovideendobronchialtreatments
Toruleoutalveolarhemorrhage
The timing of bronchoscopy is controversial, althoughyields increase when performed during or
within48hoursofbleeding.
131
Bronchial and pulmonary arteriography is performed in the setting of persistent, recurrent, or
massivehemoptysis.
Advantages:
Can be both diagnostic andtherapeutic via simultaneous embolization of the visualizedculprit
vessel.
Useful in hemoptysis of varying degrees in the setting of different etiologies including
bronchiectasis,malignancy,aspergilloma,andothers.
133
CanbeprecededbyCTangiographyforprocedureplanning.
129
Disadvantages:
Variableandinexactlocalizationofthebleedingsourcedependingonclinicalsetting.
130
Anatomicvariability.
Bleedingincaseswhereitisinsufficientforcontrastextravasation.
TREATMENT
Theapproachtohemoptysisisprimarilyaimedatdistinguishingmassive/life-threateninghemoptysis
fromnonmassivehemoptysis.Thethreemaingoalsare:
https://t.me/med1917

Nonmassivehemoptysisisusuallytreatedconservatively.Treatmentmayincludethefollowing:
Reversalofcoagulopathy
Antitussives
Bronchoscopyifrecurrent
Steroidsand/orimmunosuppressionforrheumatologicconditions
Antibioticsforinfection(fungal,TB,mycobacteria)
Diureticsand/orinotropesforheartdisease(LVfailure,mitralstenosis)
Massive hemoptysis: management requires urgent action, intensive care monitoring, and an early
multidisciplinary approach including an interventional pulmonologist, a thoracic surgeon, and an
interventionalradiologist(seeFigure10-5).
Initialstabilization:
Airwaymanagementmayrequireintubation,withalarge(>8mm)endotrachealtube.
134
□ Single-lumenmainstemintubationforselectiveventilationofunaffectedlung.
□ Double-lumenendotrachealintubationfor selective ventilationofunaffectedlung.Shouldbe
performedandmanagedonlyunderappropriatelyskilledsupervision.
Lateraldecubituspositioning(affectedlungdown)tominimizeaspirationintounaffectedlung.
Inhaledtranexamicacidmayreducevolumeofexpectoratedblood,reducehospitallengthofstay,
leadtomorefrequentresolutionofhemoptysis,reducerecurrencerates,andreducetheneedfor
invasive procedures, withoutincreased adverse effects noted.More investigation is needed on
thisintervention.
135
Bronchoscopywithdirectedairwaytherapy:Rigidbronchoscopyisfavoredifavailablebecauseit
provides optimal airway access and ventilatory control and easier suctioning and allows for
manipulationofinstruments.
Directtamponadewiththedistalendofthebronchoscope.
Balloon tamponade: Left in place for 1–2 days. Monitor for ischemic mucosal injury or
postobstructive pneumonitis.
136
Fogarty balloons, bronchial blockers, and pulmonary artery
catheterballoonshaveallbeendescribedfortamponadingbleeding.
Endobronchialelectrocautery.
137
Argonplasmacoagulation.
137,138
Endobronchialstentplacement.
139
Topical hemostatic agents: Cold saline, epinephrine, vasopressin, thrombin, and oxidized
regeneratedcellulosehavebeenusedtocontrolbleeding.
140–142
Arteriographyandembolizationshouldbeperformedearlyinmassiveorrecurrenthemoptysis.
Successfulembolizationin>85%ofcasescanbeachievedwithcarefullocalization.
133,143
Embolizationisparticularlyusefulincysticfibrosis(CF)patients.
144,145
Treatmentfailureisusuallybecauseofinadequateorincompletesourcevesselidentification.
Postembolization arteriography may identify additional systemic culprit vessels, most commonly
fromtheintercostalandphrenicarteries.
146
Rebleeding is common in embolized patients, occurring in up to 20% of cases over 1 year.
Rebleedingappearstobemorecommoninpatientswithsarcoidosis,malignancy,andaspergilloma.
143,147,148
Risksincludebronchialorpartialpulmonaryinfarctionand,rarely,ischemicmyelopathybecauseof
inadvertentembolizationofaspinalartery.
Medications
https://t.me/med1917

Systemicprocoagulants:Theseareusedonlyinunstablemassivehemoptysisasatemporizingmeasure.
Alternatively,theymayberequiredwhenconventionalbronchoscopic,interventional,orsurgical
therapiesarecontraindicatedand/orunavailable.ExamplesareadministrationoffactorVII,vasopressin,
andaminocaproicacid.
SurgicalManagement
Emergentsurgeryhashighmorbidityandmortalitycomparedwithelectivesurgeryfollowingpatient
stabilization.
119
Lobectomyorpneumonectomyoffersdefinitivecure.
Indications: Persistent focal/unilateral massive hemoptysis despite other therapy. It is
particularly useful for stable patients with hemoptysis due to cavitary lung disease, localized
bronchogeniccarcinoma,AVM,ortraumaticinjuries.
149
Contraindications:Poorpulmonaryreserve,advancedmalignancy,activeTB,diffuselungdisease,
ordiffusealveolarhemorrhage.
Referral/Consultation
Pulmonary(interventionalformassivehemoptysis,ifavailable)
Thoracicsurgery
Interventionalradiology
Outcome/Prognosis
Mortalitydependsonetiologyandvolumeofhemoptysis.
119,150,151
Mortalitymaybeashighas80%incasesofmassivehemoptysisbecauseofmalignancy.
Mortalitytendstobe<10%withnonmassivehemoptysis.
Mortalityinpatientswithbronchiectasisandlunginfectionsis<1%.
CysticFibrosis
GENERALPRINCIPLES
Definition
CFisanautosomalrecessivedisordercausedbymutationsoftheCFtransmembraneconductance
regulatorgene(CFTR),whichresultsinmultisystemexocrineorgandysfunction.
Epidemiology
IntheUS,>30,000peopleareaffectedbyCF,andabout1000newcasesarediagnosedeveryyear.
152,
153
CFisthemostcommonlife-shorteninggeneticdiseaseinCaucasians;however,thediagnosisshouldbe
consideredinpatientsofdiverseethnicbackgroundsaswell.
Theprognosis ofCFhas continuouslyimproved,andtoday>50% ofpatientswith CF intheUS are
aged≥18years.
Etiology
https://t.me/med1917

CFiscausedbymutationsintheCFTRgene,acyclicadenosinemonophosphate–regulatedchloride
channel,whichnormallymaintainshydrationofexocrineorgansecretions.
AbnormalCFTRfunctioncausesdecreasedchloridesecretionandincreasedsodiumabsorptiononthe
surfaceofepithelialcells,whichcanresultinthickenedsecretionsintheairways,sinuses,pancreatic
ducts,biliarytree,intestines,andreproductivetract.
CFTRmutationsarecategorizedintofive classes:(1)defective synthesis,(2)defectiveprocessing
and maturation, (3) defective regulation, (4) defective conductance, and (5) reduced
function/synthesis.
ThemostcommonmutationisF508del,aclassIImutationresultingfromthedeletionofDNAcoding
forphenylalanine(F) amino acid atposition508. Themajority oftheresultant misfolded proteinis
destroyedintracellularlyanddoesnotreachthecellsurface.Morethan85%ofpatientsintheUSwith
CFhaveatleastonecopyofthismutation.
153
Todate,>2000otherpotentiallycausativemutationsintheCFTRgenehavebeenidentified.
153
Pathophysiology
TheprimarypulmonarymanifestationsofCFarerelatedtothemalfunctionofchloridetransportacross
the airway epithelium, resulting in diminished airway surface liquid and impaired mucociliary
clearance.
Poor mucociliary clearance, infection, inflammation, and chronic airway obstruction often result in
bronchiectasis,chronicinfection,respiratoryfailure,andprematuredeath.
Similarly,thickenedsecretionsinthepancreaticandbiliaryductsleadtomaldigestion,malabsorption,
and,occasionally,liverdiseaseanddiabetes.
154
DIAGNOSIS
Today,childrenwithCFaretypicallydiagnosedvianewbornscreeningorduringchildhood,butthere
isincreasingrecognitionofmildervariantsthatmaynotpresentuntillaterinlife.
In2018,62%ofnewdiagnosesweretheresultofnewbornscreening.
153
Newbornscreeningis now
routinelyperformedthroughouttheUS.
AdiagnosisofCFismadewhenthereare:
155
CompatibleclinicalfeaturesofCFor
ApositivefamilyhistoryofCFor
Apositivenewbornscreeningtestand
Elevated(>60mmol/L)sweatchlorideor
Intermediate(30–59mmol/L)sweatchlorideand
Presenceoftwodisease-causingmutationsinCFTRor
AbnormalCFTRfunctionalassay
AdiagnosisofCF-relatedmetabolicsyndromeis madewhenthereisapositivenewbornscreening
test, and an intermediate sweat chloride level without two causative mutations, or a negative (<30
mmol/L) sweat chloride level with two CFTR mutations, at least one with unclear phenotypic
consequences.
Althoughgenotypingmayassistinthediagnosis,italonecannotestablishorruleoutthediagnosisof
CF,andtheinitialtestofchoiceremainsthesweatchloridetest.
ClinicalPresentation
Pulmonarymanifestations:
https://t.me/med1917

Cough with purulent sputum production, wheezing, hemoptysis, dyspnea, progressive airflow
obstruction,bronchiectasis,andpneumothorax.
Extrapulmonarymanifestations:
Chronic sinusitis, nasal polyposis, pancreatic insufficiency (vitamins A, D, E, and K deficiency),
steatorrhea, malnutrition, failure tothrive, meconium ileus, distal intestinal obstruction syndrome,
volvulus, intussusception, rectal prolapse, diabetes mellitus, liver cirrhosis, portal hypertension,
cholelithiasis,cholecystitis,nephrolithiasis,maleinfertility(bilateralabsenceofthevasdeferens),
epididymitis,growthretardation,hypertrophicpulmonaryosteoarthropathy,andosteopenia.
OlderpatientswithundiagnosedCFoftenstrugglewithrecurrentsinopulmonaryinfections,refractory
uncontrolled asthma, multiple episodes of pneumonia, unexplained bronchiectasis, recurrent
pancreatitis, or male infertility. Diagnosis at an older age is generally associated with milder
phenotypesandrarermutations.
DifferentialDiagnosis
Primaryciliarydyskinesia:Bronchiectasis,sinusitis,andinfertility.LimitedGIsymptomsandnormal
sweat chloride levels. Occasionally seen with dextrocardia or situs inversus totalis (Kartagener
syndrome).
Immunodeficiency (e.g., severe combined immunodeficiency, common variable
immunodeficiency): Recurrent sinus and pulmonary infections but typically no GI symptoms and
normalsweatchloridelevels.
Alpha-1 antitrypsin deficiency: Early-onset emphysema, airflow obstruction, chronic sputum
production,panniculitis,chronichepatitis,cirrhosis,andhepatocellularcarcinoma.Bronchiectasisisa
commonradiographicfeature
156
withnormalsweatchloridelevels.
Shwachman–Diamondsyndrome:Pancreaticinsufficiency,cyclicneutropenia,andshortstature.May
leadtolungdisease,butnormalsweatchloridelevels.
157
Youngsyndrome:Bronchiectasis,sinusitis,andazoospermia.Mildrespiratorysymptoms,lackofGI
symptoms,andnormalsweatchloridelevels.
Idiopathicbronchiectasis
DiagnosticTesting
Skin sweat testing with a standardized quantitative pilocarpine iontophoresis method remains the
goldstandardforthediagnosisofCF.
158
A sweat chloride concentration of ≥60 mmol/L on two separate occasions is consistent with the
diagnosisofCF.
Intermediatesweattestresults(30–59mmol/Lsweatchloride)ornondiagnosticresultsshouldlead
torepeatsweattesting,genetictesting,ornasalpotentialdifferencetesting.
AnormalsweatchlorideconcentrationisgenerallysufficienttoruleoutCF,butshouldberepeated
in cases with a high clinical suspicion as normal values can be observed with very uncommon
mutations.
SweattestingshouldbeperformedataCFcarecentertoensureaccuracyofresults.
Abnormalsweatchlorideconcentrationsarerarelydetectedinnon-CFpatients.
Genetictestshavedetected>2000putativeCFmutations.
TworecessivemutationsonseparateallelesmustbepresenttocauseCF.
CommerciallyavailableCFscreensidentify>90% oftheabnormal genesinaCaucasianNorthern
European population, although they test for only a minority of the known CF genes. Full gene
sequencingiscommerciallyavailable,butinterpretationmaybecomplex.Informationaboutspecific
https://t.me/med1917

mutationsandreportedclinicalphenotypemaybefoundathttp://www.cftr2.org/.
LABORATORIESANDTESTING
CXRs often demonstrate hyperinflation with upper lobe–predominant cystic lung disease,
bronchiectasis,andmucusplugging.
High-resolutionCTscansmaybehelpfulinevaluatingpatientswithearlyormilddiseasebydetecting
earlyairwaychanges.
PFTsoftendemonstrateexpiratoryairflow obstruction with increased residual volume (air trapping)
andtotal lungcapacity (hyperinflation).Impairment ofalveolar gasexchangemaybepresent laterin
thecourseofdisease.
Sputumcultures typicallyidentify multiple organisms including Staphylococcus aureus, nontypeable
Haemophilus influenzae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and
Burkholderia cepacia complex. Isolation of mucoid variants of P. aeruginosa from the respiratory
tractoccursfrequently.Useofspecialculturemediaforfastidiousorganismsisrecommended.
Nontuberculousmycobacteria(NTM)arealsofrequentlyisolatedfromtheairwaysofpersonswithCF
andmaybepathogenic.
TREATMENT
CFtherapyaimstoimprovequalityoflife,decreasethenumberofexacerbationsandhospitalizations,
reducetherateofdeclineinlungfunction,anddecreasemortality.
AcomprehensiveprogramprovidedatanaccreditedCFcarecenterisrecommended.
Treatmentburdencanbe a significantbarriertoproperadherence.Themediannumberofminutesto
completedailytherapiesisover90min/d.
ChronicTherapies
PULMONARYTHERAPY
Primarilyfocusedonclearingpulmonarysecretionsandcontrollinginfection.
Inhaled bronchodilators: β-Adrenergic agonists (such as albuterol, salmeterol, or formoterol).
Recommendedinall CFpatients. Used totreat the reversible component ofairflow obstruction and
facilitatemucusclearance.
RecombinanthumanDNase(dornasealpha,Pulmozyme):DigestsextracellularDNA,decreasingthe
viscoelasticityofthesputum.Improvespulmonaryfunctionanddecreasestheincidenceofrespiratory
tractinfectionsthatrequireparenteralantibiotics.
159
Hypertonicsaline(4 mL of inhaled 7% saline): Improves clearance ofsecretions, resultsinfewer
exacerbations, and improves lung function.
160
Albuterol should be administered prior to reduce
bronchospasm.
Mechanical airway clearance devices (oral oscillating device, high-frequency chest oscillation
vests): Used in combination with medical therapy to promote airway clearance. Other alternatives
include postural drainage with chest percussion andvibration. Exercise is also anexcellentformof
airwayclearance.
Immunizations: PneumovaxandPrevnar13are recommendedfor all patientswithCF,asis yearly
influenzavaccination.
ANTIBIOTICS
https://t.me/med1917

P. aeruginosa is the most prevalent organism in CF patients and is associated with significant
morbidity and mortality. Over time, the percentage of patients colonized with P. aeruginosa (and
multidrug-resistantPseudomonas)increases.
InpatientschronicallyinfectedwithP.aeruginosa,theinhaledaerosolizedantibioticstobramycin(300
mg nebulized twice daily) and aztreonam lysinate (75 mg nebulized 3× daily) can be used by
alternating28daysonwith28daysoff.Theseimprovepulmonaryfunction,decreasethedensityofP.
aeruginosa,anddecreasetheriskofhospitalization.Continuousalternatinginhaledantibiotictherapy
hasbecomethestandardofcareformanypatientswithchronicPseudomonasinfectionandpulmonary
impairment.
ANTI-INFLAMMATORYTHERAPY
Azithromycin (500 mgoral 3×/wk)usedchronicallyshows mildimprovementinlungfunction and
reducesdaysinthehospitalfortreatmentofrespiratoryexacerbations.Patientsshouldbescreenedfor
NTM beforeinitiationofmacrolide antibiotics becausechronicmonotherapycanlead tomacrolideresistantNTM.
Glucocorticoidsusedinshortcoursesmaybehelpfultosomepatientswithasthma-likesymptoms,but
long-termtherapyshouldbeavoidedtominimizethesideeffects.
RESTORATIONOFCFTRFUNCTION
Recently, effectivemodulator therapy hasdramaticallychanged the treatment ofCFandchanged the
diseasecourseformanypatients.
CFTR modulators treat the underlying cause of the disease by correcting protein misfolding,
transportingCFTRtothecellsurface,andrestoringchlorideconductance.
CFTRcorrectorsincreasetheamountofmatureCFTRonthecellsurfacewhilepotentiatorsincrease
thechannel-gatingactivityofCFTRprotein.
Thecombinationofcorrectorsandapotentiatorismoreeffectivethaneitherapproachalone.
SeeTable 10-11for details regarding the currently Food andDrug Administration–approved CFTR
modulators. One should note that the indications for CFTR modulators are constantly changing
especiallywithrespecttoagecutoffs.
TABLE10-11
CURRENTLYFDA-APPROVEDCFTRMODULATORS
CFTR
Modulator
FDA-Approved
Indications
Mechanism
ofAction
ClinicalEffects Adverse
Effects
SingleTherapy
Ivacaftor
(Kalydeco)
>4mowithresponsive
partialfunctionCFTR
mutations
PotentiatoraImprovesFEV1
Weightgain
Reduces
hospitalizationsand
exacerbation
frequency
Decreases
Pseudomonas
Transaminitis
c
https://t.me/med1917

airwayinfection
Improvessinus
disease
DualTherapy
Lumacaftor–
ivacaftor
(Orkambi)
>2ywithtwocopiesofthe
F508delmutation
Potentiator
plus
corrector
b
b
Modestly
improvesFEV1
Reduces
hospitalizationsand
exacerbation
frequency
Transaminitis
Lumacaftoris
apotent
inducerof
CYP3A
Chest
discomfort
anddyspnea
Tezacaftor–
ivacaftor
(Symdeko)
>6ywithtwocopiesofthe
F508delmutationor>1
otherresponsiveCFTR
mutations
Potentiator
plus
corrector
ImprovesFEV1
Reduces
hospitalizationsand
exacerbation
frequency
Transaminitis
Fewer
adverse
effectsthan
lumacaftor–
ivacaftor
TripleTherapy
Elexacaftor–
tezacaftor–
ivacaftor
(Trikafta)
>12yandatleastonecopy
ofF508delmutationora
responsiveCFTRmutation
>90%ofpatientswithCF
intheUSareeligiblefor
thistherapy
Potentiator
plustwo
correctors
Significantly
improvesFEV1
(increasedby13.8
pointsat4wk)
63%lowerannual
rateof
exacerbation
comparedto
placebo
Transaminitis
GIupset
Elevated
bilirubin
Generalapproachtoinitiationoftherapy:Ifapatienthasagenotypethatiseligibleformorethanonetherapy,generally
recommendedtostartmaximaltherapyavailableforthatagegroup(tripletherapy>doubletherapy>singletherapy).Advance
therapywhenpatientmeetsagecriteriaforeachcombinationdrug.DoseadjustmentinChild–PughClassBcirrhosis,avoidin
Child–PughclassCdisease.ReducedosewhencoadministeredwithCYP3Ainhibitors.Seepackageinsert.CF,cysticfibrosis;
CFTR,CFtransmembraneconductanceregulatorgene;FDA,FoodandDrugAdministration;FEV1,forcedexpiratoryvolumein
thefirstsecond.
a
Potentiator:IncreasesCFTRchannelopentimeatthecellsurface.
b
Corrector:IncreasescellsurfaceproteinexpressionbyimprovingtheprocessingandtraffickingofCFTR.
c
LFTsarerecommendedpriortoinitiationofCFTRmodulatortherapy,every3monthsforthefirstyear,andannuallythereafter.
PULMONARYREHABILITATION
Pulmonaryrehabilitationmayimprovefunctionalstatusandpromoteclearanceofairwaysecretions.
OXYGENTHERAPYANDNONINVASIVEVENTILATION
OxygentherapymaybeindicatedbasedonstandardrecommendationsforthetreatmentofCOPD.Rest
andexerciseoxygenassessmentsshouldbeperformedasindicated.
https://t.me/med1917

OxygenmaybeindicatedforpatientswitharestingPaO2≤55mmHgorSpO2≤88%atrestorPaO2≤
59 mm Hg or SpO2 ≤ 89% with certain comorbidities (right heart failure, cor pulmonale, or
erythrocytosis).
NocturnalnoninvasiveventilationmaybeindicatedforpatientswithadaytimerestingPCO2>50mm
Hgoranocturnaloxygensaturation<88%formorethan5minutesonusualdaytimeoxygen.
MANAGEMENTOFEXTRAPULMONARYMANIFESTATIONS
Pancreaticinsufficiency
Primary managementinvolves pancreaticenzyme supplementation.Enzymedose should be titrated
toachieveonetotwosemisolidstoolsperdayandtomaintainadequategrowthandnutrition.
Enzymesaretakenimmediatelybeforemealsandsnacks.
Dosing of pancreatic enzymes shouldbe initiated at 500 units lipase/kg/meal and should notexceed
2500unitslipase/kg/meal.
Vitamindeficiency
VitaminsA,D,E,andKcanallbetakenorallywithmealsandenzymes.
Irondeficiencyanemiarequiresironsupplementation.
CF-relateddiabetesmellitus
Related to pancreatic insufficiency and managed with insulin; oral hypoglycemics are not
recommended.
Typicaldiabeticdietaryrestrictionsareliberalized(high-caloriedietwithunrestrictedfat)tomeetthe
increased energy requirements of patients with CF and to encourage appropriate growthandweight
maintenance.
ItisrecommendedthatpregnantwomenwithCFundergoscreeningforgestationaldiabeteswith oral
glucosetolerancetestatboth12–16weeksandat24–48weeksgestation.
Bowelimpaction/distalintestinalobstructionsyndrome
Presents as colicky abdominal pain. Radiographic pattern consistent with a complete or partial
obstruction.
Laxatives such as senna, magnesium citrate, or polyethylene glycol canbe tried initially. Refractory
casesmayrequireahypaqueenemawithvisualizationofclearanceoftheobstruction.
Narcotic use and/or significant dehydration and/or nonadherence with pancreatic enzyme
supplementationcanprecipitateseverebowelobstruction.
CF-relatedliverdisease
HepatobiliarymanifestationsrangefrommildabnormalitiesinLFTstohepaticsteatosisorcirrhosis.
Mostcasesofcirrhosisarediagnosedduringchildhood(<18years).
Osteopenia
ScreeningshouldberoutinelyperformedonpatientswithCF.
Managedwithcalcium,vitaminDsupplementation,andbisphosphonatetherapyasclinicallyindicated.
Chronicsinusitis
Manypatientswillbenefitfromchronicnasalsteroidadministrationandnasalsalinewashes.
Patientswhosesymptomscannot becontrolledwithmedicalmanagementmaybenefitfromfunctional
endoscopicsinussurgeryandnasalpolypectomy.
Mentalhealth
DepressionandanxietyarecommonamongpatientsandcaregiversofCFpatientsandbothpatientsand
caregiversshouldbescreenedonaregularbasis.
Psychologicalsymptomsareassociatedwithworseadherence,heath-relatedqualityoflife,decreased
lungfunction,andlowerBMI.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана
